ClinicalTrials.gg
RecruitingNCT06615050Updated Oct 22, 2026

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

A Phase 3 interventional study of Tacrolimus (Tac) and Methotrexate (MTX) in Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation. Recruiting at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing methotrexate in Graft vs Host Disease — 3 open to participants now, 3 under way, 2 of them phase 3. Methotrexate · Graft vs Host Disease.

Planned enrollment
Largest of 22
572 · median 64
Started
2025
the only one that year
Phase 3
6 of 24
2 open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Incyte Corporation

Among the 24 studies testing methotrexate in Graft vs Host Disease, this one has the largest planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 3, and was the 24th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

3 of the 24 studies testing methotrexate in Graft vs Host Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing methotrexate in Graft vs Host Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

03

Conditions studied

  • Graft-versus-host Disease (GVHD)

Keywords

  • Graft-versus-host Disease (GVHD)
  • Chronic GvHD (cGvHD)
  • steroid-refractory
  • ruxolitinib
  • Janus kinase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18.0 years or older at the time of enrollment.
  • Participants undergoing HCT for one of the following indications:

    • Acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than 5% blasts in the bone marrow. Therapy related myeloid neoplasms are allowed.
    • Myelodysplasia/chronic myelomonocytic leukemia with no circulating blasts and with less than 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \< 5% versus 5-10% blasts in this disease). Therapy related myeloid neoplasms are allowed.
    • Lymphoma [follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma].
  • Planned NMA/reduced intensity conditioning regimen.
  • Participants must have a related or unrelated PBSC donor as follows:

    • Sibling donor must be a 6/6 match for HLA-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation. HLA-matched parents and children may be used as donors.
    • Unrelated donor must be a 7/8 or 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells and meet NMDP criteria for donation.
    • Donor selection must comply with 21 CFR 1271.
  • Cardiac function: at least 45%.
  • Estimated greater than 60 ml/min/1.73 m2 using the 2021 CKD-EPI formula Note: For eligibility, GFR by 2021 CKD-EPI is required. A baseline by Cockcroft-Gault should be done to establish baseline CrCl for ruxolitinib dosing.
  • Pulmonary function: DLCO corrected for at least 40% and predicted at least 50%.
  • Liver function: /ALT \< 3x ; Total \< 2 mg/dL excluding Gilbert's syndrome or hemolysis.
  • Performance Score of at least 60%.
  • Female participants (unless for at least one year before the screening visit, or surgically sterilized), agree to practice two effective methods of at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the through 15 months post-transplant. Fertility preservation methods will be left to institutional standards.
  • Male participants (even if surgically sterilized), of partners of women of must agree to one of the following: practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 15 months post-transplant.
  • Plans for the use of targeted small molecule inhibitor post-transplant maintenance therapy must be disclosed upon enrollment and must be used irrespective of the outcome of the randomization. Planned use of maintenance agents is not permitted. Planned hypomethylating agents as maintenance therapy is not permitted.
  • Voluntary written consent obtained prior to the performance of any study-related procedure that is not a part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion criteria

Exclusion Criteria:

  • Prior transplant.
  • Active CNS involvement by malignant cells.
  • Participants with secondary AML arising from myeloproliferative neoplasms or secondary AML arising from overlap syndromes, including CMML and MDS/MPN syndromes; participants with secondary AML arising from myelodysplastic neoplasm are eligible.
  • Participants with primary, post-Essential Thrombocythemia (post-ET) and post-Polycythemia Vera (post-PV) myelofibrosis.
  • Participants with uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.
  • Active or inadequately treated latent infection with Mycobacterium tuberculosis (i.e., TB).
  • Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use .
  • Participants seropositive for (HIV) with detectable viral load. HIV+ participants with an undetectable viral load on antiviral therapy are eligible.
  • Evidence of uncontrolled virus (HBV) or virus (HCV). The study allows:

    • Positive HBV serology with undetectable viral load and ongoing antiviral prophylaxis to prevent potential HBV reactivation.
    • Positive HCV serology with quantitative PCR for plasma HCV RNA below the lower limit of detection, with or without concurrent antiviral HCV treatment.
  • Arterial or venous thrombosis including DVT, PE, stroke, and myocardial infarction within six (6) months prior to enrollment or (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia. Catheter-associated DVT is not exclusionary.
  • Female participants who are pregnant (as per institutional practice) or lactating.
  • Participants with a serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Participants with prior except resected non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously must be reviewed and approved by the Protocol Officer or Chairs.
  • Planned use of ATG or alemtuzumab in conditioning regimen.
  • Planned use of prophylactic donor leukocyte infusions.
  • Prior use of ruxolitinib.
  • Prior use of (i.e., PD1, PDL1, CTLA4 modulators) within six (6) months prior to conditioning.
  • For participants with 7/8 HLA-matched donors:

    • Donor specific antibodies (DSAs) directed at the mismatched donor allele.
    • Any use of desensitization protocols.
  • Treatment with any other Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as medications without any known FDA or EMA approved indications.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
572 participants (estimated)

Study arms

  • Experimental
    Dose Finding Run-In Group 1: Tac/MTX/Ruxolitnib Dose 1

    Tacrolimus/ methotrexate/ ruxolitinib (Tac/MTX/Rux) at the protocol defined doses.

    Drug: Tacrolimus (Tac) · Drug: Methotrexate (MTX) · Drug: Ruxolitinib (Rux)

  • Experimental
    Dose Finding Run-In Group 2: Tac/MTX/Ruxolitnib Dose 2

    Tacrolimus/ methotrexate/ ruxolitinib (Tac/MTX/Rux) at the protocol defined doses.

    Drug: Tacrolimus (Tac) · Drug: Methotrexate (MTX) · Drug: Ruxolitinib (Rux)

  • Experimental
    Main Study Group A: Tac/MTX/Ruxolitnib

    Tacrolimus/ methotrexate/ ruxolitinib (Tac/MTX/Rux) at the protocol defined doses.

    Drug: Tacrolimus (Tac) · Drug: Methotrexate (MTX) · Drug: Ruxolitinib (Rux)

  • Active comparator
    Main Study Group B: PTCy/Tac/MMF

    Post-transplant cyclophosphamide/ tacrolimus/ mycophenolate mofetil (PTCy/Tac/MMF) at the protocol defined doses.

    Drug: Tacrolimus (Tac) · Drug: Cyclophosphamide · Drug: Mycophenolate mofetil (MMF)

Interventions

06

What researchers measure

Primary outcomes

  1. GVHD-free survival (GFS)

    GFS will be defined as the elapsed time between the date of transplant to Grade III-IV acute graft-versus host disease (GVHD), chronic GVHD requiring systemic immune suppression, or death by any cause.

    Time frame: Up to 24 months post-transplant (Day 0)

Secondary outcomes

  1. GVHD/relapse or Progression-free Survival (GRFS)

    Defined as Grade III-IV acute GVHD, chronic GVHD requiring systemic immune suppression, underlying disease relapse or progression, or death by any cause.

    Time frame: Up to 24 months post-transplant (Day 0)

  2. Incidence of chronic GVHD

    Defined by the protocol.

    Time frame: Up to 24 months post-transplant (Day 0)

  3. Incidence of acute grade 2-4 and 3-4 graft versus host disease (GVHD)

    Defined by the protocol.

    Time frame: Up to 24 months post-transplant (Day 0)

  4. Time to neutrophil and platelet recovery

    Defined by the Protocol.

    Time frame: Up to 24 months post-transplant (Day 0)

  5. Donor Cell Engraftment

    Defined by the protocol.

    Time frame: Up to 24 months post-transplant (Day 0)

  6. Cumulative incidence of primary and secondary graft failure

    Primary graft failure is defined as no neutrophil recovery to \> 500 cells/μL by Day 28 post HSCT. Secondary graft failure is defined as initial neutrophil engraftment followed by subsequent decline in absolute neutrophil counts \< 500 cells/μL, unresponsive to growth factor therapy, but cannot be explained by disease relapse or medications up to two years post-transplant.

    Time frame: Day 28 and up to 2 years post-transplant (Day 0)

  7. Disease Relapse or Progression

    Defined by the protocol.

    Time frame: Up to 24 months post-transplant (Day 0)

  8. Non-relapse Mortality

    Defined as death without evidence of disease progression or recurrence.

    Time frame: Up to 24 months post-transplant (Day 0)

  9. Toxicity and Infections

    All Grade 2-5 toxicities according to CTCAE, version 5.0 will be tabulated for each intervention arm. The proportion of participants developing at least a Grade 2 or higher toxicity across intervention arms will be compared.

    Time frame: Up to 24 months post-transplant (Day 0)

  10. Disease-Free Survival

    Defined as the time from date of transplant to death or relapse/progression, whichever comes first.

    Time frame: Up to 24 months post-transplant (Day 0)

  11. Overall Survival

    Defined as the time interval between date of transplant and death from any cause.

    Time frame: Up to 24 months post-transplant (Day 0)

  12. Modified Lee Chronic GVHD Symptom Scale (mLSS)

    The modified Lee chronic GVHD symptom scale (mLSS) is a 28 item measure with seven domains referent to the past seven days: skin, mouth, eye, lung, psychoemotional, vitality and nutrition.

    Time frame: Up to 24 months post-transplant (Day 0)

  13. Individual Symptom Scale: Modified Medical Research Council (mMRC) Dyspnea scale

    mMRC dyspnea scale assesses the degree of functional disability due to dyspnea.

    Time frame: Up to 24 months post-transplant (Day 0)

  14. Individual Symptom Scale: Two items from a protocol defined survey

    Two items from a protocol defined survey are used to measure hemorrhagic cystitis symptom burden.

    Time frame: Up to 24 months post-transplant (Day 0)

  15. Individual Symptom Scale: Oral Health Impact Profile (OHIP)

    OHIP measures dysfunction, discomfort and disability caused by oral conditions.

    Time frame: Up to 24 months post-transplant (Day 0)

  16. Individual Symptom Scale: Ocular Surface Disease Index (OSDI)

    OSDI measures symptoms and vision effects of dry eye disease.

    Time frame: Up to 24 months post-transplant (Day 0)

  17. Work Productivity and Impairment Questionnaire (WPAI)

    WPAI measures the impact on ability to work and perform regular activities.

    Time frame: Up to 24 months post-transplant (Day 0)

  18. Comprehensive Score for Financial Toxicity (COST)

    COST measures the impacts of treatment on finances and economic status of the patient households.

    Time frame: Up to 24 months post-transplant (Day 0)

  19. Patient-Reported Economic, Income and Insurance Data (PREIID)

    PREIID measures the impacts of treatment on finances and economic status of the patient households.

    Time frame: Up to 24 months post-transplant (Day 0)

  20. Patient Reported Caregiver Assessment (PRCA)

    PRCA measures the type of support provided by caregivers, and the economic burden to patient caregivers.

    Time frame: Up to 24 months post-transplant (Day 0)

07

Study locations

30 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2031, 69 months after the start.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 26, 2024
StartActual
Apr 2, 2025
Primary completionEst.
Jan 17, 2031
CompletionEst.
Jan 17, 2031
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06615050
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Apr 2, 2025
Primary completion
Jan 17, 2031 (estimated)
Completion
Jan 17, 2031 (estimated)
Last update
Oct 22, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Ruxolitinib

Start the discussion